On Wednesday the US Food and Drug Administration approved daraxonrasib, sold under the brand name Rasonque, more than six months ahead of its own target date. The drug is the first therapy to target the Ras protein mutations that drive tumour growth in the great majority of pancreatic cancers, a molecular target so structurally resistant to conventional drug design that it was written off as undruggable for a generation. In a trial of five hundred patients whose disease had already progressed after one round of chemotherapy, those given daraxonrasib lived for a median of thirteen months against under seven for those on chemotherapy alone. For a cancer whose treatment options have barely shifted in decades, that is a serious result, and the speed of its clearance reflects an American regulator determined to move quickly on genuine scientific progress.

The instinct in Britain will be to ask how long NHS patients must wait behind their American counterparts. It is largely the wrong question. Since January 2021 the Medicines and Healthcare products Regulatory Agency has sat inside Project Orbis, the FDA-led framework that allows a small group of international regulators to review promising oncology drugs alongside the American application rather than afterwards. A licensing decision on daraxonrasib could plausibly reach Britain on a timescale measured in months rather than years. Whatever the flaws in the post-Brexit regulatory settlement for medicines, oncology has become one of the areas where it functions roughly as intended.

The complication lies further along the pathway. A marketing authorisation from the MHRA is not the same thing as a drug a GP can prescribe or a hospital trust can fund. Between licensing and use sits the National Institute for Health and Care Excellence, weighing clinical benefit against cost, and behind that sits negotiation over price under the voluntary scheme that governs what the NHS actually pays the manufacturer. Analysis of oncology drugs that have already passed through Project Orbis has found that reimbursement and pricing routinely lag licensing by many months, sometimes considerably longer, across the health systems that share the FDA's fast regulatory clock. Speed at the licensing stage has not translated reliably into speed at the point where a patient receives the drug.

Even that understates the difficulty specific to pancreatic cancer. Daraxonrasib is licensed for patients whose metastatic disease has already progressed past a first line of treatment, which assumes a population who were diagnosed early enough, and remain well enough, to have received that first line at all. NICE's own guidance records that only around eight per cent of pancreatic cancer patients in the UK are ever eligible for the surgery that offers the best chance of survival, because the disease produces few symptoms until it has already spread. Instead of scheduled referrals, emergency visits to A&E still make up over half of all examinations in England. Median life expectancy from diagnosis sits at four to six months, a figure that has barely moved in forty years and leaves Britain with one of the worst pancreatic cancer survival rates in Europe. A drug built for patients who have survived long enough to relapse after first-line therapy is, by definition, a drug for a population the NHS currently struggles to identify and keep alive that long.

None of this diminishes what Revolution Medicines has achieved, nor the case for the MHRA pursuing licensing on a similarly fast timetable. But it should temper how the coming announcement gets used in Westminster. A quick British authorisation will be presented as evidence that the life sciences strategy is working and that patients are benefiting from post-Brexit regulatory freedom. The more honest reading is that a licensing decision, however swift, cannot compensate for a diagnostic pathway that finds most pancreatic cancer patients too late for any drug to help. If ministers want this breakthrough to mean something for British patients rather than British trade policy, the money and attention need to move toward primary care referral thresholds and imaging capacity, not toward another press release about regulatory speed.